Alkermes (ALKS)
Develops and sells neuroscience medicines spanning addiction, psychiatry and sleep disorders.
$43.70
vs last close−0.48 (−1.09%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 107.47% | 180.29M shares | |
|---|---|---|---|
| 437 holders · as of Jun 30, 2026 | |||
| Insiders | 0.65% | 1.10M shares | |
| 14 holders · as of Sep 3, 2026 | |||
| Adds to | 108.12% | ||
167.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 108.12%; nothing is left for Other.
13F, as of Jun 30, 2026
437 holders · 180.29M shares · 90 new positions · 232 increased · 137 reduced · 57 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 29.24M | 17.43% | +921.3K | Aug 7, 2026 |
| Baker Bros. Advisors LP | 10.01M | 5.97% | 0 | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 9.49M | 5.66% | −20.3K | Aug 13, 2026 |
| State Street Corp | 9.16M | 5.46% | −304.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 7.52M | 4.48% | +87.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.74M | 4.02% | +2.07M | Aug 14, 2026 |
| Renaissance Technologies LLC | 6.46M | 3.85% | +300.5K | Aug 13, 2026 |
| Geode Capital Management, LLC | 4.48M | 2.67% | +295.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.80% | 25.64M | 13G | Apr 28, 2025 |
| Baker Bros. Advisors LP | 6.10% | 10.01M | 13G | Feb 17, 2026 |
| Vanguard Portfolio Management | 5.80% | 9.65M | 13G | Apr 28, 2026 |
| Vanguard Capital Management | 5.21% | 8.68M | 13G | Apr 28, 2026 |
| State Street Corporation | 5.20% | 8.54M | 13G | Nov 10, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 3, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $48.01 | 223,422 |
| Sep 1, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $46.99 | 65,389 |
| Aug 17, 2026 | Christian Todd Nicholsofficer: SVP, Chief Commercial Officer | Sale · 2 lots | 7,576 | $49.23 | 102,193 |
| Aug 3, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $48.58 | 225,456 |
| Aug 3, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $48.58 | 69,389 |
| Aug 3, 2026 | nancy lynn MD snydermandirector | Sale | 44,472 | $50.35 | 15,395 |
| Jul 6, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $54.03 | 227,490 |
| Jul 1, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale · 2 lots | 9,000 | $51.51 | 73,389 |
| Jun 12, 2026 | Christopher I. Wrightdirector | Sale | 2,000 | $45.10 | 25,680 |
| Jun 4, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43.05 | 229,524 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Ray Cisneros · CA31 | Purchase | $15,001 – $50,000 | Jul 30, 2026 | Sep 7, 2026 | |
| Rep. Gilbert Ray Cisneros · CA31 | Purchase | $15,001 – $50,000 | Jul 29, 2026 | Sep 7, 2026 |